Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 1998

View Archived Issues

Amgen: Q4 and FY 1997 highlights

Cel-Sci updates shareholders

Celtrix: Q3 highlights

DiagnoCure: Q4 and FY 1997 highlights

Allergan: FY 1997 highlights

Panretin update

Plant extract DA-9601 protects against NSAID-induced gastric damage

Adenosine agonists with antilipolytic activity described by Glaxo

Icos reveals new cGMP-specific PDE inhibitors

Byk Gulden describes new imidazopyridine PDE IV inhibitors

Celltech reports crosslinked antibodies for cancer indications

Potential new antimigraine agents in development at Allelix

Novel approach to HIV therapy described by ML Laboratories

Zeneca's new antibacterial agents active against resistant pathogens

Inhibitors of secretory PLA2 produced by Streptomyces violaceusniger

Chinese investigators evaluate new MDR-reversing agent

Goralatide: a candidate hematopoietic agent from Beaufour Ipsen

Roche develops orally active anti-HSV agent that targets viral TK

U.S. clearance for naratriptan

CytRx to divest Proceutics subsidiary

Chiroscience and Bristol-Myers Squibb collaborate on MMP inhibitors for cancer

Immunomedics terminates CEA-Scan marketing agreements with Mallinckrodt

Synercid scheduled for FDA committee review next week

Neurocrine Biosciences and Rigel collaborate on gliosis inhibitors

Micrologix, PENCE to collaborate on new antibiotics

Medarex and Schering AG sign antibody agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...